Nurture growth: Ketogenic diet therapy and growth velocity in infants under 12 months with epilepsy - A systematic

Anika Maass1, Francesca Sutter2, Petra Trimmel-Schwahofer2

  • 1Children's Hospital AUF DER BULT, Hannover, Germany.

PubMed

Insights

Ketogenic diet therapy (KDT) does not impede growth in infants during the first year of life when monitored. However, growth velocity may decrease in the second year of KDT treatment.

Area of Science:

  • Pediatric Neurology
  • Nutritional Science
  • Epileptology

Background:

  • Ketogenic diet therapy (KDT) is an established treatment for early infantile epilepsy.
  • The effect of KDT on infant growth remains a subject of debate.
  • Previous studies have yielded conflicting results regarding growth parameters during KDT.

Purpose of the Study:

  • To evaluate the impact of early Ketogenic Diet Therapy (KDT) on growth velocity and height percentiles in infants.
  • To systematically review existing literature on KDT and infant growth.
  • To analyze data from a prospective cohort of infants treated with KDT.

Main Methods:

  • Systematic literature review of studies on infant growth (<12 months) under KDT.
  • Analysis of a prospective database of 63 infants (<12 months) receiving KDT.
  • Assessment of growth velocity z-scores, height/weight SD, BMI, and macronutrient intake.

Main Results:

  • Literature review (7 studies) showed varied growth outcomes; growth velocity data was limited.
  • In the prospective cohort, median growth velocity z-score was 1.03 in the first year.
  • No decrease in growth velocity or height percentiles was observed up to one year of age with KDT.

Conclusions:

  • KDT, with adequate nutritional monitoring, does not negatively impact infant growth in the first year.
  • Growth velocity may decline in the second year of KDT treatment.
  • Early epilepsy onset and earlier KDT initiation correlated with slower first-year growth velocities.

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
351
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
301
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
273
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
462